Diagnosis of Alzheimer’s disease (AD) is often difficult because of distinct and subjective clinical features, especially in the early stage. FOXO3a protein present in the cognitive centre of brain in inferior temporal region and parahippocampus. FOXO3a can be a potential novel target against AD. AD, Mild Cognitive impairment (MCI) and Geriatric Control (GC) were recruited after diagnosis by clinical assessment, MRI, TauPET and FDG-PET. We have quantified serum FOXO3a by surface plasmon resonance (SPR) and compare with TauPET between of AD, MCI patients and GC. Serum FOXO3A was significantly lower in AD (1.42 ± 0.09 ng/μl) compare to MCI (1.61 ± 0.14 ng/μl) and GC (1.89 ± 0.07 ng/μl). However, the Tau was higher in AD both in serum and also in PET scan. Serum pTau was significantly over-expressed in AD (0.176 ± 0.03 ng/μl), compare to other groups; MCI (0.16 ± 0.014 ng/μl) and GC (0.15 ± 0.024 ng/μl). Serum FOXO3A could significantly differentiate AD vs MCI, MCI vs GC and AD vs GC. However, Tau protein could only differentiate AD vs GC but not MCI vs GC. Serum FOXO3A may serve as novel blood marker for early detection for AD and target for therapeutic intervention.

阿尔茨海默病 (AD) 的诊断通常很困难，因为其具有独特的主观临床特征，尤其是在早期阶段。FOXO3a 蛋白存在于颞下区和海马旁的大脑认知中心。FOXO3a 可能是对抗 AD 的潜在新靶点。在通过临床评估、MRI、TauPET 和 FDG-PET 诊断后招募 AD、轻度认知障碍 (MCI) 和老年控制 (GC)。我们通过表面等离子体共振 (SPR) 量化了血清 FOXO3a，并与 AD、MCI 患者和 GC 之间的 TauPET 进行了比较。与 MCI (1.61 ± 0.14 ng/μl) 和 GC (1.89 ± 0.07 ng/μl) 相比，AD 中的血清 FOXO3A (1.42 ± 0.09 ng/μl) 显着降低。然而，无论是在血清中还是在 PET 扫描中，AD 中的 Tau 都较高。与其他组相比，血清 pTau 在 AD 中显着过度表达 (0.176 ± 0.03 ng/μl)；MCI (0.16 ± 0.014 ng/μl) 和 GC (0.15 ± 0.024 ng/μl)。血清 FOXO3A 可以显着区分 AD 与 MCI、MCI 与 GC 和 AD 与 GC。然而，Tau 蛋白只能区分 AD 与 GC，而不能区分 MCI 与 GC。血清 FOXO3A 可作为新的血液标志物用于 AD 的早期检测和治疗干预的靶点。